{"organizations": [], "uuid": "1aa691d8ecfd1025b8bf359bf6e166d0760a7cc1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-eisai-submits-snda-to-fda-for-fyco/brief-eisai-submits-snda-to-fda-for-fycompa-pediatric-indications-idUSASC09UD3", "country": "US", "domain_rank": 408, "title": "BRIEF-Eisai Submits sNDA To FDA For Fycompa Pediatric Indications", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-30T22:12:00.000+03:00", "replies_count": 0, "uuid": "1aa691d8ecfd1025b8bf359bf6e166d0760a7cc1"}, "author": "", "url": "https://www.reuters.com/article/brief-eisai-submits-snda-to-fda-for-fyco/brief-eisai-submits-snda-to-fda-for-fycompa-pediatric-indications-idUSASC09UD3", "ord_in_thread": 0, "title": "BRIEF-Eisai Submits sNDA To FDA For Fycompa Pediatric Indications", "locations": [], "entities": {"persons": [{"name": "fycompa pediat", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "eisai inc", "sentiment": "none"}, {"name": "eisai", "sentiment": "none"}, {"name": "eisai inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 30, 2018 / 7:13 PM / Updated 22 minutes ago BRIEF-Eisai Submits sNDA To FDA For Fycompa Pediatric Indications Reuters Staff \nMarch 30 (Reuters) - Eisai Inc : \n* EISAI SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) TO FDA FOR FYCOMPAÂ® (PERAMPANEL) PEDIATRIC INDICATIONS \n* EISAI INC - SUBMISSION ALSO PROPOSES PEDIATRIC INDICATION FOR MONOTHERAPY, ADJUNCTIVE USE FOR PGTC SEIZURES IN CHILDREN WITH EPILEPSY \n* EISAI INC SAYS SNDA IS FOR BOTH FYCOMPA TABLET AND ORAL SUSPENSION FORMULATIONS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-30T22:12:00.000+03:00", "crawled": "2018-03-30T22:47:51.011+03:00", "highlightTitle": ""}